(LNTH) Lantheus Holdings - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5165441032
LNTH: DEFINITY, TechneLite, Cardiolite, Xenon-133, PYLARIFY
Lantheus Holdings, Inc. (NASDAQ:LNTH) is a leader in the development, manufacturing, and commercialization of innovative diagnostic and therapeutic products. The company focuses on addressing critical needs in cardiology, oncology, and other diseases, delivering solutions that enhance clinical decision-making and patient outcomes. Its portfolio includes a range of imaging agents and therapeutics, such as DEFINITY for echocardiography, PYLARIFY for prostate cancer imaging, and Neurolite for stroke assessment. Additionally, Lantheus offers advanced software solutions like aPROMISE and PYLARIFY AI, leveraging artificial intelligence to improve diagnostic accuracy. The company is also advancing a robust pipeline, including investigational agents targeting Alzheimers disease, neuroendocrine tumors, and prostate cancer. Strategic collaborations with industry leaders like GE Healthcare and Regeneron further strengthen its position in the market. With a strong foundation since 1956, Lantheus continues to innovate, supported by its headquarters in Bedford, Massachusetts.
3-Month Forecast:
Additional Sources for LNTH Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
LNTH Stock Overview
| Market Cap in USD | 7,460m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Health Care Supplies |
| IPO / Inception | 2015-06-25 |
LNTH Stock Ratings
| Growth Rating | 75.9 |
| Fundamental | 81.5 |
| Dividend Rating | 0.0 |
| Rel. Strength | 12.5 |
| Analysts | 4.62/5 |
| Fair Price Momentum | 96.11 USD |
| Fair Price DCF | 154.19 USD |
LNTH Dividends
No Dividends PaidLNTH Growth Ratios
| Growth Correlation 3m | 55.4% |
| Growth Correlation 12m | 14.6% |
| Growth Correlation 5y | 89.1% |
| CAGR 5y | 44.41% |
| CAGR/Max DD 5y | 0.91 |
| Sharpe Ratio 12m | 0.62 |
| Alpha | -0.44 |
| Beta | 0.652 |
| Volatility | 185.64% |
| Current Volume | 2977.4k |
| Average Volume 20d | 729.2k |
As of May 09, 2025, the stock is trading at USD 80.44 with a total of 2,977,395 shares traded.
Over the past week, the price has changed by -24.06%, over one month by -13.89%, over three months by -7.44% and over the past year by +7.96%.
Yes, based on ValueRay Fundamental Analyses, Lantheus Holdings (NASDAQ:LNTH) is currently (May 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 81.54 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LNTH as of May 2025 is 96.11. This means that LNTH is currently undervalued and has a potential upside of +19.48% (Margin of Safety).
Lantheus Holdings has received a consensus analysts rating of 4.62. Therefor, it is recommend to buy LNTH.
- Strong Buy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, LNTH Lantheus Holdings will be worth about 106 in May 2026. The stock is currently trading at 80.44. This means that the stock has a potential upside of +31.79%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 134.9 | 67.7% |
| Analysts Target Price | 134.4 | 67.1% |
| ValueRay Target Price | 106 | 31.8% |